SCMP Financial Facts
Diluted net income (loss) per share: -0.08Contract and collaboration revenue: 164K
See Full Income Statement
Commitments (Note 7): 0
Accrued expenses: 7.85M
See Full Balance Sheet
Earnings History for Sucampo Pharmaceuticals (SCMP)
|
Expand Research on SCMP
| Next EPS Date | 6/7/13 *Est. | EPS Growth Rate | +433.3% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -308.3% | Revenue Growth Rate | +145.4% *Last Qtr. |
| Average % Move 1-Wk after EPS | +32.1% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/13/13 |
Q412 | $0.32 | $0.12 | +$0.20 | $34.9M | $32.21M | N/A / N/A | N/A | +81.8% | Details | |
| 3/13/12 |
Q411 | $0.06 | N/A | N/A | $14.22M | $15.9M | N/A / N/A | N/A | +18.9% | Details | |
| 11/3/11 |
Q311 | -$0.10 | N/A | N/A | $14.37M | $20.9M | N/A / N/A | N/A | +125% | Details | |
| 3/3/11 |
Q410 | -$0.15 | -$0.01 | -$0.14 | $12.4M | $15.5M | N/A / N/A | N/A | +110.3% | Details |
